Compare Uranium Energy Corp (UEC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Uranium Energy Corp trades at $9.19 (market cap $4.53B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.2× Uranium Energy Corp's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Uranium Energy Corp for 37 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UEC | XBI | |
|---|---|---|
Market Cap | $4.53B | $10.11B |
Volume | 10,888,578 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $20.14 | $169.55 |
52-Week Low | $9.04 | $104.99 |
Typical Hold Time | 37 Days | 38 Days |
Enterprise Value | $4.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Uranium Energy (UEC) trades at $9.14, down 3.48% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M but a net loss of $137M, reflecting operational challenges. Recent news highlights production expansion at two U.S. mines and unhedged sales strategy delivering $93.13 per pound realized price. Cash flow remains negative from operations but positive overall due to significant financing activities.
UEC faces fundamental headwinds with negative profitability metrics and high valuation ratios, though Wall Street maintains bullish sentiment with 87.5% buy ratings and $16.06 consensus price target. Key risks include production sustainability questions and dependence on uranium price volatility. The stock offers speculative upside if operational improvements materialize amid growing nuclear energy demand.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
